

Executes a UK Strategic Partnership with LINK Medical Solutions

Highlights

- ✓ Initial market entry activities commence for access to the UK market for ColoSTAT®; and
- ✓ Completes a UK Strategic partnership with LINK Medical Solutions Ltd.

As per Appendix 4C on 27 April 2023, transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (**ASX: RHY**) (**Rhythm** or the **Company**) is pleased to confirm it has progressed its market entry of ColoSTAT® into the United Kingdom (UK) post approval of the UKCA Mark Certification.

Colorectal Cancer in the UK

The UK (England, Scotland, Wales and Northern Ireland) has a population of approximately 10.8 million people in the current addressable Colorectal Cancer (CRC) screening market aged from 60 to 74. The UK utilises the Faecal Immunochemical Test (FIT) as a screening methodology with a participation rate of 63-71% from the age of 60 to 74.¹

The UK has 13.2 million people aged between 45 to 60. Each year 15% of all new CRC cases are within this age group. This is an opportunity for ColoSTAT® to provide an alternative screening method for individuals that will or cannot participate in the current screening program.

Strategic Partnership with LINK Medical Solutions

Rhythm has signed a Strategic Partnership with London-based medical technology consultancy and provider LINK Medical Solutions Ltd (LINK). LINK is committed to enhancing the quality of life and clinical outcomes for patients worldwide. Since its inception in 2016, LINK has been at the forefront of implementing transformational medical technologies.

Specialising in the commercialisation and distribution of innovative medical products, LINK have extensive experience in launching new technologies in the UK, South Africa, and Scandinavian countries. With a proven track record of launching over 30 medical products, LINK provides an indispensable approach for companies aiming to bring their innovative medical technologies to market, such as US-based Tempus' comprehensive genomic profiling (CGP) portfolio.

The strategic partnership will provide Rhythm with a phased approach to successful market entry, which includes:

- local clinical validation;
- market access into the private and public healthcare systems;
- a broader distribution of ColoSTAT® within the UK.
- stakeholder mapping & engagement;
- access ultimately to the National Institute for Health and Care Excellence (NICE) guidance; and

LINK Managing Director, Sasha Becejac, said: "I am thrilled to announce our strategic partnership with Rhythm to bring ColoSTAT® to the market in the UK. This collaboration marks a significant milestone in revolutionising early detection & diagnosis in colorectal cancer that will enable many patients to be treated earlier."

Chief Commercial Officer of Rhythm, Ms Elena Deak, commented: "The team are very excited and looking forward to progressing with LINK Medical Solutions in the UK market. LINK's extensive experience in commercialising innovative medical technologies will create our UK footprint and deliver our goal in having our test available to the international market as an alternative to the current CRC screening method."

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Otto Buttula
Trevor Lockett
Rachel David
Louis Panaccio
Sue MacLeman

Executive Chairman
Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr Otto Buttula Executive Chairman	Ms Elena Deak Chief Commercial Officer	Mr Paul Smith CFO & Company Secretary
--	--	---

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About LINK Medical Solutions

LINK Medical Solutions Ltd (LINK) is a London-based company committed to enhancing the quality of life and clinical outcomes for patients worldwide. Since its inception in 2016, LINK has been at the forefront of implementing transformational medical technologies.

With a proven track record of commercialising over 30 medical products, LINK provides indispensable consultancy and distribution services to companies aiming to bring their innovative medical technologies to market.

LINK has established a substantial presence in the UK, Nordics, and South Africa, distributing ground-breaking medical solutions that disrupt the status quo and advance healthcare possibilities.

At LINK, the future of medical technology is being built today, with a dedication to improved patient care at its core.

¹ <https://www.cancerresearchuk.org>